05/08/2025 17:00
Days
Hours
Mins
Secs
Until At the Heart of Cardiovascular Disease Prevention 2025 Begins
Details
This evening dinner symposium will educate physicians, advanced care providers and the broader healthcare team on current guidelines and opinion on the identification of risk factors, prevention measures and treatment options for cardiovascular disease. Don't miss out on early bird special pricing!
Date & Time: Thursday May 8, 2025 | 5:00pm - 8:30pm
Location: Olympic Hills Golf Club | 10625 Mt Curve Rd, Eden Prairie, MN 55347
Meet the Faculty
Agenda
5:00pm-6:00pm | Registration, Buffet Dinner & Exhibits |
6:00pm-6:10pm | Welcome (Michael Miedema, MD, MPH) |
6:10pm-6:30pm | Expanding Choices in Lipid Management (Thomas Knickelbine, MD) |
6:30pm-6:50pm | Understanding Women's Cardiovascular Disease Risk (Elizabeth Tuohy, MD) |
6:50pm-7:10pm | Revolutionizing CV Health - The Impact of GLP-1 Medications (Michael Miedema, MD, MPH) |
7:10pm-7:30pm | AI in Cardiovascular CT - Current State and Future Directions (Jonathan Urbach, MD) |
7:30pm-8:00pm | Expert Roundtable (Moderated by Michael Miedema, MD, MPH) |
8:00pm-8:30pm | Exhibits |
Accreditation
Allina Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Allina Health designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designed to meet the Minnesota Board of Nursing continuing education requirements for 2.0 hours of credit.
Learning Objectives
- Discuss medications that can be used in addition to statins for LDL lowering.
- Outline heart disease pathophysiology and considerations unique to women.
- Identify female-specific risk factors for cardiovascular disease.
- Recall current information on the role of GLP-1 medications in cardiovascular disease prevention.
- Outline current and future applications of artificial intelligence in cardiovascular CT and its potential impact on patient care and outcomes.
Target Audience
Primary Care, Internal Medicine, Family Medicine, OB/GYN and Cardiology Physicians, Advanced Practice Providers (Nurse Practitioner and Physician Assistants) and other health care professionals on their care teams
Thank You Exhibitors!
Alnylam | NewAmsterdam Pharma |
Amgen | Novartis |
BridgeBio | Novo Nordisk |
CMP Pharma | Regeneron |
Edwards Lifesciences | United Therapeutics |
J&J MedTech |